Investor Relations

PrimeVax is a clinical stage biotechnology company with our first indication for PD-1 failed melanoma. We opened our first IND with the FDA and are currently mobilizing our clinical trial sites. A non-confidential slide deck may be provided for potential partnership contacts. 


For business development inquiries, please email:



© 2020 PrimeVax Immuno-Oncology